Andreas Carus

761 total citations
30 papers, 493 citations indexed

About

Andreas Carus is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Carus has authored 30 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Carus's work include Bladder and Urothelial Cancer Treatments (11 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Urinary and Genital Oncology Studies (5 papers). Andreas Carus is often cited by papers focused on Bladder and Urothelial Cancer Treatments (11 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Urinary and Genital Oncology Studies (5 papers). Andreas Carus collaborates with scholars based in Denmark, Sweden and United Kingdom. Andreas Carus's co-authors include Henrik Hager, Morten Ladekarl, Frede Donskov, Bettina S. Nedergaard, Patricia Switten Nielsen, Hans K. Pilegaard, Sture Falkmer, Jens Sandahl Christiansen, Jens Overgaard and Christian Djurhuus and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes and British Journal of Cancer.

In The Last Decade

Andreas Carus

29 papers receiving 490 citations

Peers

Countries citing papers authored by Andreas Carus

Since Specialization

Citations

This map shows the geographic impact of Andreas Carus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Carus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Carus more than expected).

Fields of papers citing papers by Andreas Carus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Carus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Carus. The network helps show where Andreas Carus may publish in the future.

Co-authorship network of co-authors of Andreas Carus

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Carus. A scholar is included among the top collaborators of Andreas Carus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Carus. Andreas Carus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brain metastasis in a patient with metastatic urothelial carcinoma after 7 years of avelumab maintenance therapy: A case report 2025 ·Urology Case Reports ·(unknown), (unknown), (unknown), (unknown), Andreas Carus	0
2	Longer survival with precision medicine in late-stage cancer patients 2025 ·ESMO Open ·Christophe K. Mapendano, (unknown), Mads Sønderkær, (unknown), Andreas Carus, (unknown), Charlotte Aaquist Haslund, Laurids Østergaard Poulsen, Anja Ernst, Julie Støve Bødker, (unknown), Lone Sunde, (unknown), (unknown), Inge Søkilde Pedersen, Morten Ladekarl	2
3	1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial 2024 ·Annals of Oncology ·Jørgen Bjerggaard Jensen, Karin Birkenkamp‐Demtröder, Iver Nordentoft, (unknown), (unknown), (unknown), (unknown), Gitte Wrist Lam, (unknown), (unknown), Andreas Carus, Astrid Petersen, Ulla Nordström Joensen, Helle Pappot, P.S. Holt, Niels Viggo Jensen, Mads Agerbæk, Lars Dyrskjøt	15
4	Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations 2024 ·JCO Oncology Practice ·Mohammed Munavvar, Uffe Bødtger, Andreas Carus, Rosa Cordovilla, Samir Naik, Antonieta Salud, José M. Porcel	1
5	Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study 2024 ·European Journal of Cancer ·Thomas Wagner, Birgitte Grønkær Toft, Jakob Lauritsen, Mikkel Bandak, Ib Jarle Christensen, (unknown), Michael Kreiberg, Mads Agerbæk, Lars Dysager, Andreas Carus, (unknown), Daniel M. Berney, Gedske Daugaard	6
6	DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer 2024 ·Scandinavian Journal of Urology ·(unknown), Thomas Dreyer, Andreas Carus, (unknown), Ulla Nordström Joensen, Gitte Wrist Lam, Niels Viggo Jensen, (unknown), (unknown), Helle Pappot, Mads Agerbæk, Jørgen Bjerggaard Jensen	2
7	Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors 2023 ·Cancers ·(unknown), Morten Ladekarl, Henrik Hager, (unknown), (unknown), (unknown), (unknown), (unknown), Andreas Carus	2
8	The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial 2023 ·Journal of Patient-Reported Outcomes ·Gry Assam Taarnhøj, Christoffer Johansen, Andreas Carus, Rikke Hedegaard Dahlrot, (unknown), Niels Henrik Hjøllund, (unknown), Anders Tolver, Henriette Lindberg, Helle Pappot	3
9	50P Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study 2023 ·ESMO Open ·Christophe K. Mapendano, (unknown), Andreas Carus, Tamás Lörincz, (unknown), Charlotte Aaquist Haslund, (unknown), (unknown), Martin Bøgsted, Inge Søkilde Pedersen, Morten Ladekarl	1
10	1556MO The iBLAD study: Patient-reported outcomes in bladder cancer during oncological treatment: A multicenter national randomized controlled trial 2022 ·Annals of Oncology ·Gry Assam Taarnhøj, (unknown), Andreas Carus, Rikke Hedegaard Dahlrot, (unknown), (unknown), Helle Pappot	1
11	GLIM diagnosed malnutrition predicts clinical outcomes and quality of life in patients with non-small cell lung cancer 2022 ·Clinical Nutrition ·(unknown), (unknown), Andreas Carus, Henrik Højgaard Rasmussen	14
12	Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark 2021 ·Bladder Cancer ·(unknown), (unknown), (unknown), Andreas Carus, Anne Birgitte Als, Niels Viggo Jensen, Gry Assam Taarnhøj, Anders Tolver, Helle Pappot	3
13	Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen 2021 ·Bladder Cancer ·(unknown), (unknown), Anne Birgitte Als, Mads Agerbæk, (unknown), Henriette Lindberg, Niels Viggo Jensen, Andreas Carus, (unknown), Abolfazl Hosseini, Cecilia Radkiewicz, Helle Pappot, Anders Ullén	4
14	1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort 2020 ·Annals of Oncology ·(unknown), (unknown), Mette Poehl, Morten Ladekarl, (unknown), (unknown), (unknown), Peter Meldgaard, Karin Holmskov Hansen, (unknown), Charlotte Kristiansen, (unknown), (unknown), (unknown), Gitte Fredberg Persson, (unknown), (unknown), Andreas Carus	1
15	Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment 2020 ·Clinical Nutrition ·(unknown), Andreas Carus, H.H. Rasmussen, Sture Falkmer, Martin Grønbech Jørgensen, Erik Berg Schmidt, (unknown), Esben Bolvig Mark, Agnieszka Delekta, (unknown), Martin Bøgsted, Mette Holst	24
16	Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study 2020 ·European Urology Open Science ·(unknown), (unknown), Henriette Lindberg, Andreas Carus, Anne Birgitte Als, Niels Viggo Jensen, Gry Assam Taarnhøj, Redas Trepiakas, Charlotte Suetta, Lars Haukali Omland, Helle Pappot	20
17	Exploring the dietary protein intake and skeletal muscle during first-line anti-neoplastic treatment in patients with non-small cell lung cancer 2019 ·Clinical Nutrition ESPEN ·(unknown), H.H. Rasmussen, Mette Holst, (unknown), Sture Falkmer, Martin Bøgsted, Agnieszka Delekta, Andreas Carus	10
18	Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM) 2019 ·European Journal of Cancer ·(unknown), Niels Viggo Jensen, (unknown), (unknown), (unknown), Mads Agerbæk, Cecilia Nilsson, (unknown), Andreas Carus, (unknown), (unknown), Yvonne Brandberg, Hemming Johansson, Mats Hellström, Hans von der Maase, Helle Pappot, Anders Ullén	16
19	Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome 2013 ·Lung Cancer ·Andreas Carus, Morten Ladekarl, Henrik Hager, Hans K. Pilegaard, Patricia Switten Nielsen, Frede Donskov	95
20	Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer 2013 ·British Journal of Cancer ·Andreas Carus, Morten Ladekarl, Henrik Hager, Bettina S. Nedergaard, Frede Donskov	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact